Review
Version 1
Preserved in Portico This version is not peer-reviewed
p38 MAPK Molecular Targeting for Next-Generation Multiple Myeloma Therapy
Version 1
: Received: 29 December 2023 / Approved: 3 January 2024 / Online: 4 January 2024 (05:44:50 CET)
A peer-reviewed article of this Preprint also exists.
Morales-Martínez, M.; Vega, M.I. p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. Cancers 2024, 16, 256. Morales-Martínez, M.; Vega, M.I. p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. Cancers 2024, 16, 256.
Abstract
Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 MAPK has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.
Keywords
multiple myeloma; p38 mapk; transcriptional factor; cancer progression; clinical implication; gene expression
Subject
Medicine and Pharmacology, Hematology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
